WDH Stock Chart & Stats
€15.40
€0.70(3.93%)
At close: 4:00 PM EST
€15.40
€0.70(3.93%)
Day’s Range― - ―
52-Week Range€11.60 - €18.70
Previous CloseN/A
Volume0.00
Average Volume (3M)10.00
Market Cap
€7.44B
Enterprise Value€74.19B
Total Cash (Recent Filing)€1.33B
Total Debt (Recent Filing)€20.99B
Price to Earnings (P/E)37.1
Beta0.70
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.52
Shares Outstanding423,506,600
10 Day Avg. Volume0
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)4.48
Price to Sales (P/S)1.92
P/FCF Ratio13.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsVery high gross margin (~75.6%) indicates strong product economics and pricing power in core hearing-aid products. This durable margin buffer supports reinvestment, cushions cost pressure and helps absorb lower ASPs, aiding sustained profitability recovery over the next 2–6 months.
Strong Cash Generation / FCF ConversionFree cash flow conversion around 84% of net income and robust operating cash flow demonstrate the business converts earnings to cash efficiently. Durable cash generation supports deleveraging, funds integration and restructuring costs, and finances clinic and product investments without needing immediate equity raises.
KIND Acquisition Expands Clinic FootprintKIND expands Demant's clinic network and scale in Germany (#1 position targeted) and adds recurring service revenue and cross-sell opportunities. The expected ~DKK300m EBIT contribution and integration synergies create a lasting structural uplift to Hearing Care profitability and diversification of revenue mix.
Bears Say
Elevated Leverage After AcquisitionMaterial rise in leverage (debt-to-equity ~2.13; gearing ~3.4x) reduces financial flexibility and raises refinancing and covenant risk. Management paused buybacks to prioritize deleveraging to a 2.0–2.5 target, which can constrain strategic investment or make the firm vulnerable to earnings volatility during recovery.
Weakened Operating And Net MarginsSubstantial declines in EBIT and net margins point to persistent cost, mix and operating-leverage pressures despite strong gross margins. This reduces retained cash for debt reduction and investment and means margin recovery depends on successful cost programs and KIND synergies, which take time to realize.
Market Softness And Competitive PressureStructural softness in key markets and share losses in the U.S., driven by retailer dynamics and low-price competitive launches, threaten sustainable top-line recovery and pricing power. Prolonged weak demand or channel displacement would slow deleveraging and limit the impact of cost programs.
Demant News
WDH FAQ
What was Demant’s price range in the past 12 months?
Demant lowest stock price was €11.60 and its highest was €18.70 in the past 12 months.
What is Demant’s market cap?
Demant’s market cap is €7.44B.
When is Demant’s upcoming earnings report date?
Demant’s upcoming earnings report date is Aug 11, 2026 which is in 30 days.
How were Demant’s earnings last quarter?
Demant released its earnings results on Feb 03, 2026. The company reported €0.137 earnings per share for the quarter, beating the consensus estimate of N/A by €0.137.
Is Demant overvalued?
According to Wall Street analysts Demant’s price is currently Overvalued.
Does Demant pay dividends?
Demant does not currently pay dividends.
What is Demant’s EPS estimate?
Demant’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Demant have?
Demant has 423,506,600 shares outstanding.
What happened to Demant’s price movement after its last earnings report?
Demant reported an EPS of €0.137 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.389%.
Which hedge fund is a major shareholder of Demant?
Currently, no hedge funds are holding shares in DE:WDH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Demant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.99%
12-Months-Change
Fundamentals
Return on Equity
16.06%
Trailing 12-Months
Asset Growth
36.36%
Trailing 12-Months
Company Description
Demant
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
Technical Analysis
Insulet
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Steris
―
Zimmer Biomet Holdings
―